The usage of PET/CT imaging in head and neck cancer

Öz

PET, is a non-invasive radiological technique which measures the tissue perfusion, metabolic activity and viability by using tomographical images and quantitative parameters. PET/CT is progressively becoming on routine usage in head and neck cancer staging. PET/BT makes the cancer staging easier by whole body scaning, by characterisation of the lymph nodes accurately ad by showing the presence of head neck tumors. In this review we searched the importance of PET/CT at staging of head neck tumors.

Key words: PET/CT, head and neck cancer, lymph node

Anahtar Kelimeler

• PET/CT, head and neck cancer

Baş boyun tümörlerinde PET/BT kullanımı

Öz

PET dokuların perfüzyonunu, metabolik aktivitesini ve canlılığını yansıtan tomografik görüntüler ve kantitatif parametrelerin kullanıldığı non-invaziv bir görüntüleme yöntemidir. Baş ve boyun tümörlerinde evrelemede PET/BT giderek artan oranda rutin kullanıma girmektedir. PET/BT tüm vücudu tarama olanağı sağlaması ve baş boyun tümörlerinde tutulum göstermesi ve lenf nodlarını doğru bir şekilde karakterize etmesi bakımından evrelemede kolaylık sağlamaktadır. Bu yazıda baş boyun tümörleri olan hastalarda evrelemede PET/BT'nin önemini araştırdık.

Anahtar kelimeler: PET/BT, baş boyun tümörleri,lenf nodu

Anahtar Kelimeler

• PET/BT, baş boyun tümörleri

Kaynakça

1. - Jeong HS, Baek CH, Son YI, et al. Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck 2007; 29: 203-10.
2. - Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480-508.
3. - Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
4. - Fukui MB, Blodgett TM, Snyderman CH, et al. Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 2005; 25: 913-30.
5. - Goerres GW, Stoeckli SJ, von Schulthess GK, Steinert HC. FDG PET for mucosal malignant melanoma of the head and neck. Laryngoscope 2002; 112: 381-5.
6. - Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol 2008; 97: 649-52.
7. - Agarwal V, Branstetter BF 4th, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin North Am 2008; 41: 23-49.
8. - Baek CH, Chung MK, Son YI, et al. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images. J Nucl Med 2008; 49: 1422-8.

9. - Leslie A, Fyfe E, Guest P, et al. Staging of squamous cell carcinoma of the oral cavity and oropharynx: a comparison of MRI and CT in T-and N-staging. J Comput Assist Tomogr 1999; 23: 43-49.
10. - Vermeersch H, Loose D, Ham H, et al. Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers. Eur J Nucl Med Mol Imaging 2003; 30: 1689-700.
11. - Dammann F, Horger M, Mueller-Berg M, et al. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol 2005; 184: 1326-31.
12. - Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008; 100: 712-20.
13. - Koshy M, Paulino AC,Howell R, et al. F-18 FDGPET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck 2005; 27: 494–502.
14. - Ha PK, Hdeib A, Goldenberg D, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132: 12–6.
15. - Goerres GW, Schmid DT, Gratz KW, et al. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2003; 39: 547–51.
16. - Roh JL, Yeo NK, Kim JS, et al. Utility of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol 2007; 43: 887-93.
17. - Yamazaki Y, Saitoh M, Notani K, et al. Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med 2008; 22: 177-84.
18. - Stoeckli SJ, Steinert H, Pfaltz M, et al. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck 2002; 24: 345-9.
19. - Civantos FJ, Gomez C, Duque C, et al. Sentinel node biopsy in oral cavity cancer: Correlation with PET scan and immunohistochemistry. Head Neck 2003; 25: 1-9.
20. - Hyde NC, Prvulovich E, Newman L, et al. A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: The role of sentinel node biopsy and positron emission tomography. Oral Oncol 2003; 39: 350-60.
21. - Scott AM, Gunawardana DH, Bartholomeusz D, et al. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med 2008; 49: 1593-1600.
22. - Fleming AJ Jr, Smith SP Jr, Paul CM, et al. Impact of 18F-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117: 1173-9.
23. - Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101: 2641-9.
24. - Gutzeit A, Antoch G, Kühl H, et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 2005; 234: 227-34.
25. - Johansen J, Buus S, Loft A, et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck 2008; 30: 471-8.
26. - Miller FR, Karnad AB, Eng T, et al. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck 2008; 30: 28-34.
27. - Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using (F-18) fluorodeoxyglucose positron emission tomography. Head Neck 1997; 19: 666-74.
28. - Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645-50.
29. - Lonneux M, Lawson G, Ide C, et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110: 1493-7.
30. - Greven KM, Williams DW 3rd, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23: 942-6.
31. - Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130: 105-9.
32. - Comoretto M, Balestreri L, Borsatti E, et al. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology 2008; 249: 203-11.
33. - Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33: 210-22.
34. - Liu T, Xu W, Yan WL, et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 2007; 85: 327-35.
35. - Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009; 50: 24-9.
36. - Wong RJ, Lin DT, Schöder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20: 4199-208.
37. - Ong SC, Schöder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med 2008; 49: 532-40.
38. - Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004; 130: 1361-7.
39. - Roh JL, Pae KH, Choi SH, et al. 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol 2007; 33: 790-5.
40. - Lee SW, Nam SY, Im KC, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008; 87: 211-6.
41. - Machtay M, Natwa M, Andrel J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009; 31: 195-201.